Table 1.
Characteristics of participants before the third dose and the fourth dose.
| Characteristics before the third dose | AZD1222 (N = 138) | BNT162b2 (N = 138) | p-values |
|---|---|---|---|
| Median (IQR), age (years) | 50.4 (44.5, 56.1) | 30.7 (27.3, 42.7) | < 0.001 |
| Female | 108 (78.3) | 90 (65.2) | 0.016 |
| Occupation | |||
| Nurse | 84 (60.9) | 55 (39.9) | < 0.001 |
| Physician | 18 (13.0) | 50 (36.2) | |
| Others | 36 (26.1) | 33 (23.9) | |
| Underlying diseases | |||
| Dyslipidemia | 31 (22.5) | 9 (6.5) | < 0.001 |
| Hypertension | 21 (15.2) | 9 (6.5) | 0.020 |
| Asthma | 7 (5.1) | 13 (9.4) | 0.164 |
| Diabetes mellitus | 7 (5.1) | 3 (2.2) | 0.335 |
| Thyroid diseases | 4 (2.9) | 2 (1.4) | 0.684 |
| Malignancy | 3 (2.2) | 1 (0.7) | 0.622 |
| Median (IQR) body mass index (kg/m2) | 23.3 (21.5, 25.9) | 22 (20.0, 25.2) | 0.008 |
| Median (IQR) duration from the second dose to the third dose (days) | 68 (51.0, 110.0) | 71 (65.0, 130.0) | 0.007 |
| Participants in whom duration from the second dose to the third dose > 90 days | 48 (34.8) | 48 (34.8) | 1.000 |
| Characteristics before the fourth dose | AZD1222 (N = 92) | BNT162b2 (N = 92) | p-values |
|---|---|---|---|
| Median (IQR), age (years) | 51.8 (46.0, 56.7) | 32.2 (27.6, 43.3) | < 0.001 |
| Female | 78 (84.8) | 62 (67.4) | 0.006 |
| Occupation | |||
| Nurse | 59 (64.1) | 40 (43.5) | < 0.001 |
| Physician | 11 (12.0) | 30 (32.6) | |
| Others | 22 (23.9) | 23 (25.0) | |
| Underlying diseases | |||
| Dyslipidemia | 23 (25.0) | 8 (8.7) | 0.003 |
| Hypertension | 15 (16.3) | 7 (7.6) | 0.069 |
| Asthma | 4 (4.3) | 11 (12.0) | 0.059 |
| Diabetes mellitus | 6 (6.5) | 2 (2.2) | 0.278 |
| Thyroid diseases | 3 (3.3) | 1 (1.1) | 0.621 |
| Malignancy | 1 (1.1) | 1 (1.1) | 1.000 |
| Median (IQR) body mass index (kg/m2) | 23.3 (21.5, 25.9) | 22.1 (19.9, 24.7) | 0.006 |
| Median (IQR) duration from the third dose to the fourth dose (days) | 147.0 (147.0, 148.0) | 155 (154.0, 155.0) | < 0.001 |
| Participants in whom duration from the third dose to the fourth dose > 90 days | 31 (33.7) | 35 (38.0) | 0.539 |
| Type of the fourth dose vaccine | |||
| mRNA-1273 | 92 (100.0) | 16 (17.4) | < 0.001 |
Categorical data are presented in number (%).